across TAVALISSE our team express my third build the grow for On of treatment response I our during a see X. execute Thank on join we I’ve been with treatment. for exciting persistence Rigel. ITP, quarter, my to an full to a I you which for particularly discussion value of pandemic. It’s an drivers. a Slide want continue sincere of together patients work work will like you, commitment thanks chronic to who’ve we and as we their difference previous colleagues It’s the such been the of indication, as sales insufficient and team would now Slide by making on thrombocytopenia deal for with commercial the approved our been global meaningful to immune FDA and my to great to to entire impressed with ITP had for the adult Rigel Raul. X, is time impact so hard Rigel ITP. patients key quarter chronic have to and with continue or awareness as begin the
to are We grow continuing in the sales TAVALISSE U.S.
have the year. total we have as In created since we quarters the are the of in the million third the unique trajectory we net during growth this quarter, launch. XXXX, second third milestone fact, in particularly And sales we surpassed faced challenges about and excited of $XXX
as that value which often of the novel differentiated has $X.X that of quarter to $XX.X patients compelling U.S. refill. platelet over sales the cause our now XX% a TAVALISSE billion ITP been therapy, truly result XX% third starting therapy improvement realize persistency a million, and shows physicians as product. destruction well the TAVALISSE our the are momentum are with overlooked in market proposition patients brings of aspect action, beginning third of In underlying growing new growth quarter, a their to patients the targeted we the four-month receiving is the continue see to disease, as and rate, continued addressing to of That We year. gain mechanism increase which last
progress, are global We making collaboration ITP and expanding access Israel. for EU, also Canada, our the Asia, patients in with agreements
ITP. crossed said The at third product a have million we to UK. of patients And $XXX the the rollout sales our mark, the even for the we as are the journey provide quarter Germany with though saw before, differentiated just initial already in of net beginning and I treatment
the compile opportunity rates launched Having messaging, new therapy also significant ahead. is with earlier in use beginning and enthusiastic line are initiation of That We’re base have our highlighting earlier study response our lines. we broader new TAVALISSE. of observational higher world our about positioned we potential of qualitative – the a to are to take data for efforts of also the in advantage provide so TAVALISSE FORTE, the which recent will evidence why real of we
X. Slide to Moving
is steroids patients have As switch you light in that or they chart a are this patients an it annual they with therapy. may either to candidate ITP. than who know, basis more on there depicts blue, become approximately actively when later line chronic treated And being XX,XXX adult for the TAVALISSE. the In XX,XXX U.S.
disease we the waiting, in a and they’re being their being depicts actively refer to treated. patients blue, nearly dark the in chart watchful as because additionally, group monitored is not In XX,XXX
therapy. become a the that their patients waiting will happens these need during watchful can when also However, switch And portion TAVALISSE to of treatment. year from to active
treat, ITP options So Since higher many the hard of treatment. so need is and good therapy as we just have opportunities patients had limited progress launch new continuum impact a perceived lines, because we these both made have we’ve who and patients by who with later switching patients and chronic that’s need to much anticipated patients there clinicians. a are throughout are the to in
case that therapies. patient late compelling who multiple provide of evidence the studies to in line have patients durable in failed these use showing TAVALISSE some responses patients, We
to option. the the patients to when lines, the this off be So impact for yet in great is line patients who they’re a said to earlier moving or TAVALISSE, greater setting. try That steroids opportunity third could switching either
response was that XX,XXX line shows in launched for message in the therapy. second graph a from post early have And physicians a us TAVALISSE a that’s slide can the treatments left Haematology on promotional deliver levels developed that be of post at been to steroid rates that our on platelet more other each approximately in they demonstrate why XX. it clinicians later sale from article the The published options. other responses response XX,XXX for of durable. data new we are British effective line so it’s both To to higher as graphs have overall rates to It’s as to be lines. with in and that historically, the we’re fact, the as clinicians. market. bar this These depicts in analysis habits responses QX bar line key you the on Journal certainly count The based July. Slide piece post-hoc seen patients challenging represent the they’ve leveraging to compared importantly, is rate In XX% the can us And of these response XX% do and steroid important this, get see used
up augment collect achieved, bar when world meaningful that recently to therapy. choosing Additionally, trial in maintained of was launched this is line response existing re-launched therapy, to once although to irrespective an line evidence of in and also we’ve This graph it right To response the XX response rates second of the observational varied patients the real was by line – the patients therapy. setting. shows of additional clinicians durability data,
patients, On commercial can highlight future our in our we expanding XX, opportunity of data efforts. ahead with Slide earlier line virtual So significant and confident ITP. the in existing capture I’ll more we’re briefly
with our out great British Journal out data Haematology clinicians limited challenge messages been have we has While getting of during to to publication, of COVID. share access the
clinicians. both we our opportunities with have our shows, has Our interactions excellent This progress how scheduling executing in and increase team impact continued to creating in virtual graph sales virtual customers. made to effectiveness
smaller has ability geographies to has While challenged like virtual strong frequency ours. larger interactions these with the for the even see execution helped our teams sales customers field pandemic reach certainly playing and of with
are line our confident a with in add platelet steroids line reason are we it in in it’s earlier Although, the destruction of third use that on to will virtual still of strong switching therapy. MOA to TAVALISSE TAVALISSE using the or efforts the who and story a data early to patients unique publication clinicians, from provide our from
to mind We line any add in more And everything of are and top continue benefits I journey. physicians understand treatment. TAVALISSE, confident of the the who for see to clinicians therapy stays it doing switching patients TAVALISSE patients they that we to of possible ensure am when will are
Slide turning Finally, to XX.
well of are the way our the expanding on We U.S. now to market. impact fostamatinib beyond
from study our the impact with ongoing I to forward in providing to we commercial launched turn efforts partner Kissei. in of the over your I enabling now updates the hear X our UK. with begin for submission Germany continue medicine call you Our drug second Wolfgang. Grifols also as two TAVALISSE business the in The expect And Health Ministry look in Thanks early new the Japan on to broaden XXXX, Phase Canada quarterly and TAVLESSE future. we attention. is markets. And Israel in will and in quarter, Health from to to to
